This meeting took place in 2019

For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Integrated Pathways of Disease in NASH and NAFLD (A4)

Organizer(s) Scott L. Friedman, Arun J. Sanyal, Brent A. Tetri, Mary E. Rinella and Christopher R. Shepard
January 20—24, 2019
Eldorado Hotel & Spa • Santa Fe, New Mexico USA
Discounted Abstract Deadline: Oct 16, 2018
Abstract Deadline: Oct 24, 2018
Scholarship Deadline: Oct 16, 2018
Discounted Registration Deadline: Nov 27, 2018

Sponsored by Gilead Sciences, Inc., Novo Nordisk A/S and Pfizer Inc.

Summary of Meeting:
The global prevalence of nonalcoholic fatty liver disease (NAFLD) has risen precipitously over the past two decades in parallel with the worldwide obesity epidemic; however, there are no approved therapies. The more advanced form of the disease, non-alcoholic steatohepatitis (NASH), is associated with progressive fibrosis and an increased risk of liver cancer. Despite the growing number of systemic and liver-specific abnormalities identified in patients with NAFLD, a clear hierarchy of the relative importance of specific defects has not emerged. Furthermore, a clear understanding of which individuals are at highest risk for progression to advanced liver disease and cancer remains elusive. Thus, the field lacks an integrated understanding of risk prediction, pathogenesis and validated biomarkers to predict or track disease progression without reliance on liver biopsies. Therefore, the goals of this conference are to: 1) Explore genetic and ethnic contributions to NAFLD development; 2) Clarify underlying pathogenic defects in NAFLD and NASH, focusing on the specific contributions of lipotoxicity, the microbiome, innate immune signaling and drivers of fibrosis; and 3) Highlight emerging prognostic and diagnostic biomarkers that are yielding new, more streamlined clinical trial designs to evaluate novel therapies. As a result of this conference, attendees should gain a more holistic understanding of the unmet needs and new paths to advancing our understanding of NAFLD pathogenesis, diagnosis and therapy. The multidisciplinary nature of the topics and speakers promises to generate novel insights that represent convergent expertise and opinion. In doing so, new paradigms are likely to emerge that greatly inform the expanding number of emerging diagnostic markers and therapeutic agents. The conference comes at a propitious time when there is already sufficient basic translational and clinical research to extract important new insights, focus on unmet needs and refine research strategies for the future.

View Meeting Program


Keystone Symposia Future of Science Fund Scholarship Recipients

Yanling Ma
National Institutes of Health, USA

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Scholarship Recipients

Bishuang Cai
Columbia University, USA

Tagreed Mazi
University of California, Davis, USA

Kristin Schwerbel
Institute of Human Nutrition, Germany

Anissa A. Widjaja
DUKE-NUS Medical School, Singapore

Hongji Zhang
Ohio State University, USA